Anemia in patients with very low, low or intermediate risk myelodysplastic neoplasms (MDS) research hub

A phase II, open-label, multicenter study of orally administered RVU120 for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (MDS)

This study is testing a new drug, RVU120, for people with a type of bone marrow problem called myelodysplastic neoplasms (MDS) who also have anaemia (low red blood cells). It looks at how well the drug helps the body make more red blood cells.